Takeda's Alunbrig meets in Phase III for first-line NSCLC
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said first-line treatment with Alunbrig brigatinib met the primary endpoint of improving independent review committee (IRC)-assessed progression-free survival (PFS) vs. Xalkori crizotinib in the Phase III ALTA-1L trial to treat non-small cell lung cancer (NSCLC). The open-label, international trial enrolled 275 patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic NSCLC who had not received prior treatment with an ALK inhibitor.
Takeda said it plans to meet with regulatory authorities to discuss expanding Alunbrig's label to include the front-line setting. The data will be submitted for presentation at a medical meeting...
BCIQ Company Profiles